SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme ( Study Showed Bioequivalence LONDON ...)

SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme

Study Showed Bioequivalence

LONDON, UK and ATLANTA, US, May 14, 2007 - SkyePharma PLC (LSE:SKP; NASDAQ:SKYE) and Sciele Pharma. Inc. (NASDAQ:SCRX) today announce the successful completion of the clinical trial programme for the new formulation of Sular, a calcium
channel blocking agent for the treatment of high blood pressure. The study results showed that the new Sular formulation is bioequivalent to Sciele's currently marketed Sular. The new Sular formulation utilizes SkyePharma's patented Geomatrix technology, which is designed to provide a lower dose of Sular for each of its current doses.

The data from this study will be combined with the results from the previous clinical trial in Sciele's new Sular formulation supplemental New Drug Application (sNDA) filing. Sciele expects to file an sNDA with the U.S. Food and Drug Administration by end of the second quarter of 2007.

For further information please contact:

SkyePharma PLC +44 20 7491 1777
Frank Condella, CEO
Ken Cunningham COO
Peter Grant Finance Director

Financial Dynamics +44 20 7831 3113

(UK Enquiries)
David Yates / Deborah Scott

Trout Group +1 617 583 1308

(US Enquiries)
Christine Labaree / Seth Lewis

About Sular

Nisoldipine, the active ingredient in Sular(R), is an antihypertensive agent used to reduce blood pressure. It is estimated that 65 million Americans (nearly one quarter of the population) currently have elevated blood pressure, a recognised risk factor for stroke and heart attacks, and this number is increasing from demographic factors a
'"/>

Page: 1 2 3
Related medicine technology :

1. Sciele Pharma Announces Successful Completion of New Sular Formulation Clinical Trial Program
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis

Post Your Comments:

(Date:12/2/2009)..., , NEW YORK, Dec. 2 /PRNewswire/ ...search report is available in its catalogue: ,,...p://www.reportlinker.com/p0164303/Arthroscopes---A...pic procedures are on rise, owing to their mountin...f ankles, elbow, wrists, and hips, apart from knee...

(Date:12/2/2009)..., , NEW YORK, Dec. 2 /PRNewswire/ -...earch report is available in its catalogue: ,, ...Perspective ,, http://www.reportlinker.com/p0...arket-Perspective.html ,, Electrodes in electr..., muscle and nerve cells that are created by chemi...

(Date:12/2/2009)..., , FRAZER, Pa., Dec. 2 /PRNewswire-...y announced that it has filed a lawsuit in U.S. Di...als USA, Inc. for infringement of U.S. Patent Nos....46 Patent") and RE37,516 (the ",516 Patent") for t...blets [C-IV]. Cephalon has a three-year period of...

Breaking Medicine Technology:Reportlinker Adds Arthroscopes - A World Market Review 2 Reportlinker Adds Arthroscopes - A World Market Review 3 Reportlinker Adds Arthroscopes - A World Market Review 4 Reportlinker Adds Arthroscopes - A World Market Review 5 Reportlinker Adds Arthroscopes - A World Market Review 6 Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 2 Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 3 Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 4 Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 5 Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 6 Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 7 Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 2 Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 3 Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals 4 Sundia in Top 100 Fast growth Outsourcing Companies in China 13084 1 ATS Medical Announces First Use of the New ATS CryoMaze 10 S Probe 52081 1 ATS Medical Announces First Use of the New ATS CryoMaze 10 S Probe 52081 2 ATS Medical Announces First Use of the New ATS CryoMaze 10 S Probe 52081 3 ATS Medical Announces First Use of the New ATS CryoMaze 10 S Probe 52081 4 Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease 3B Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver 4745 1 Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease 3B Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver 4745 2

[0] Reportlinker Adds Arthroscopes - A World Market Review [0] Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective [0] Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals

...usly Demonstrated Survival Advantages of Tarceva i...se - ABSTRACT No: 4507, ...zumab),to a combination of Tarceva (erlotinib) and...ents with metastatic pancreatic cancer live withou...urvival"). These data,presented for the first time...

...Fold More Radiation Delivered to Tumor as Compared...l Patients Surpassed Expected Median Survival Time...se Level-, CHICAGO and TUSTIN, Calif., May 31 Pe...ay reported that clinical,researchers from the Abr...nia will present data showing that its brain cance...

Other Medicine Technology:Patients with Pancreatic Cancer Can Benefit From Avastin(R) Plus Tarceva(R) 2 Patients with Pancreatic Cancer Can Benefit From Avastin(R) Plus Tarceva(R) 3 Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 2 Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 3 Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 4 Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 5

Patients with Pancreatic Cancer Can Benefit From Avastin(R) Plus Tarceva(R)Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

(Date:12/3/2009)...five pound gift anywhere in the world can easily s...wide postage is free when you send an upscale Amer...ww.oakanahouse.com . , (P...t to Paris, Perth or Punjab can easily set you bac...ey can keep in their pocket when gift buyers purch...

(Date:12/3/2009)... The Ensign Group, Inc. ...ired three Texas skilled nursing facilities: the 9...e Center in McAllen, the 100-bed Alta Vista Rehabi...95-bed Veranda Rehabilitation & Healthcare in ...r 1, 2009. ,, (Logo: http://www.newscom.com/c...

(Date:12/3/2009)...co has been the life-long focus of his research an...ombardi Comprehensive Cancer Center at Georgetown ...dit a special-edition of Cancer Epidemiology, Bio...esearch practices in tobacco science from research...P , a journal of the American Association for Canc...

(Date:12/2/2009)...Newswire-USNewswire/ -- The American Association o...nnepin Regional Poison Center in Minneapolis, Minn...ajor milestone for the center. The designation by...ter among 58 accredited poison centers in the Unit... accomplishment. It means we have met the national...

(Date:12/2/2009)...PRNewswire/ -- Reportlinker.com announces that a n...logue: ,, Renal Disease Treatments: Products a...0166824/Renal-Disease-Treatments-Products-and-Ther... products and services, providing data for 2008 an...et and compound annual growth rates (CAGRs) from 2...

[0] Greg Lawson Americana Photography Gift Books Now Offered with Free Shipping Worldwide [0] The Ensign Group Acquires Three Texas Skilled Nursing Facilities [0] Lombardi's Shields leads special journal focused on tobacco research [1] Hennepin Regional Poison Center Designated as an Accredited Poison Control Center [1] Reportlinker Adds Renal Disease Treatments: Products and Therapies

... Professor Tim Eisen has expressed concerns that p...mned to toxic, barely effective, 20 year-old treat...d Clinical Excellence (NICE) is likely to rule out...f Cambridge, points out that although NICE has put...

...9 ( www.amdl.com ) AMDL, Inc. (Amex: ADL... with major operations in China and the US, announ...ivate placement offering of 12% senior notes and w... completion of a bank or credit facility of not le...

...he S trategies t o O vercome and P revent (STO... - Guide for Policy and Program Solutions ( http:/...navigation tool developed to guide public and priv...t least $92.6 billion annually, and affects the li...

... Second Annual Children,s Flu Vaccination Day to H...ted Illnesses and Deaths , , WASHINGTON, De..., go to: http://www.prnewswire.com/mnr/fff/36289...DC) are designating today, December 9, the second...

...at by 2050, up to 16 million people will have visi... News) -- The number of Americans with diabetic re... to 16 million by the year 2050, according to a U.... cause of blindness among working-age adults in th...

...harles D. Kennedy, MD, Vice,President of Health In...WLP ),will present today at The 4th Annual World H... v.4.0), which is expected to convene with over 40...ribing: An Early Health,Information Exchange Tool,...

Other Medicine News:Health News:UK kidney cancer patients face toxic, out-dated treatments with little hope of change 2 Health News:UK kidney cancer patients face toxic, out-dated treatments with little hope of change 3 Health News:AMDL Inc. Announces Closing of Private Placement Senior Notes 2 Health News:AMDL Inc. Announces Closing of Private Placement Senior Notes 3 Health News:STOP Obesity Alliance Releases Obesity GPS to Change America's Course in the Fight Against Overweight and Obesity 2 Health News:STOP Obesity Alliance Releases Obesity GPS to Change America's Course in the Fight Against Overweight and Obesity 3 Health News:STOP Obesity Alliance Releases Obesity GPS to Change America's Course in the Fight Against Overweight and Obesity 4 Health News:Photo: Families Fighting Flu and CDC Encourage Parents to Vaccinate Kids Against Flu 2 Health News:Photo: Families Fighting Flu and CDC Encourage Parents to Vaccinate Kids Against Flu 3 Health News:Diabetic Eye Disease Rates Soaring 2 Health News:Dr. Charles Kennedy, Vice President of Health Information Technology for WellPoint, Inc., to Present Today at The 4th Annual World Healthcare Innovation and Technology Congress (WHIT v.4.0) 2

UK kidney cancer patients face toxic, out-dated treatments with little hope of change AMDL Inc. Announces Closing of Private Placement Senior Notes STOP Obesity Alliance Releases Obesity GPS to Change America's Course in the Fight Against Overweight and Obesity Photo: Families Fighting Flu and CDC Encourage Parents to Vaccinate Kids Against Flu Diabetic Eye Disease Rates Soaring Dr. Charles Kennedy, Vice President of Health Information Technology for WellPoint, Inc., to Present Today at The 4th Annual World Healthcare Innovation and Technology Congress (WHIT v.4.0)

Wis-Hipple American Profile Conventional Laryngoscopes

Miller English Profile Conventional Laryngoscopes

Miller American Profile Conventional Laryngoscopes

MacIntosh English Profile Conventional Laryngoscopes

Medicine Products:

Wis-Hipple American Profile Conventional Laryngoscopes Miller English Profile Conventional Laryngoscopes Miller American Profile Conventional Laryngoscopes MacIntosh English Profile Conventional Laryngoscopes

( Study Showed Bioequivalence LONDON ...)SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme,Health